Natco Pharma Soars After Generic Ozempic Approval | Big GLP-1 Opportunity? | Business News | ET Now скачать в хорошем качестве

Natco Pharma Soars After Generic Ozempic Approval | Big GLP-1 Opportunity? | Business News | ET Now

Natco Pharma shares rallied after the company received approval from India’s drug regulator, CDSCO, for its generic version of semaglutide — the key ingredient in Ozempic. With demand for GLP-1 drugs soaring globally due to rising diabetes and obesity cases, this approval could open up a massive growth opportunity for Natco. Will this mark the beginning of a strong revenue cycle for the pharma major? How big is the semaglutide opportunity in India and globally? Watch for full analysis on the stock’s prospects, competition, and sector impact. #natcopharma #semaglutide #ozempic #pharmastocks #stockmarketindia #glp1 #diabetescare #obesitytreatment #indianstockmarket #cdsco #pharmanews #sharemarket #investing control your money with economic times now. #etnow #businessnews #budget2026withetnow YouTube Channel -    / @etnow   Subscribe To ET Now For Latest Updates On Stocks Market News , Business News, Company News, IPO & More | https://bit.ly/SubscribeToETNow Subscribe Now To Our Network Channels :- ET Now Swadesh:    / etnowswadesh   Times Now: http://goo.gl/U9ibPb Social Media Links :- Twitter - http://goo.gl/hA0vDt Facebook - http://goo.gl/5Lr4mC Website - https://www.etnownews.com Follow us on Google News for latest updates ET Now: https://news.google.com/publications/... Times Now Navbharat: https://bit.ly/3zDaKJo Times Now : https://bit.ly/3CyrrYg Zoom: https://bit.ly/3CEK0dv